The MARIPOSA-2 trial examined the intracranial response rates in patients with EGFR-mutated NSCLC treated with amivantamab with carboplatin-pemetrexed with or without lazertinib and found that amivantamab with chemotherapy led to prolonged median intracranial PFS relative to chemotherapy alone (12.5 versus 8.3 months) [104]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.